![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MTX-101, a bispecifc autoimmune checkpoint inhibitor (KIR/CD8), into first-in-human clinical trials for the treatment of autoimmune diseases like type 1 diabetes mellitus or celiac disease.
Lead Product(s): MTX-101
Therapeutic Area: Gastroenterology Product Name: MTX-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Details:
The proceeds will be used to advance first-in-class CD8 Treg Modulators including MTX-101, a bispecifc autoimmune checkpoint inhibitor, into first-in-human clinical trials for the treatment of autoimmune diseases and to support pipeline expansion.
Lead Product(s): MTX-101
Therapeutic Area: Gastroenterology Product Name: MTX-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Ventures
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 07, 2023
Details:
The company will use the Series A funds to progress its lead CD8 Treg Modulator into the clinic while also advancing additional programs generated from its novel platform.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 26, 2021